HemaQuest Pharmaceuticals, a Seattle, WA-based clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, closed an additional $4m to its Series B financing.
The investment, which brings the total amount to Series B financing to $16m, was made by new investor Latterell Venture Partners, which joins existing backers Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.
In conjunction with the financing, James Woody, MD, PhD, General Partner at Latterell Venture Partners, has joined HemaQuest’s Board of Directors.
The financing is intended to help advance HemaQuest’s two lead products, HQK-1001 and HQK-1004, through Phase 2b clinical trials.
FinSMEs
28/07/2010